Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Novo Nordisk CEO Lars Sørensen: An Interview With "The Pink Sheet"

Executive Summary

Novo Nordisk AS turned in a strong financial showing in 2010, with sales up 13%, and the Danish company has been riding a wave of positive investor sentiment. The launch of the once-daily GLP-1 analogue Victoza (liraglutide) in the U.S. in the early part of the year helped to drive sales, but its modern insulins portfolio also continues to perform well.
Advertisement

Related Content

Topics

Advertisement
UsernamePublicRestriction

Register

PS053161

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel